A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors (Q46076293)
Jump to navigation
Jump to search
scientific article published on 24 March 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors |
scientific article published on 24 March 2009 |
Statements
1 reference
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors (English)
1 reference
Pasi A Jänne
1 reference
Kwok-K Wong
1 reference
Paula M Fracasso
1 reference
Ronald M Bukowski
1 reference
Thomas J Lynch
1 reference
Pamela N Munster
1 reference
Geoffrey I Shapiro
1 reference
Joseph P Eder
1 reference
Michael J Naughton
1 reference
Matthew J Ellis
1 reference
Suzanne F Jones
1 reference
Tarek Mekhail
1 reference
Charles Zacharchuk
1 reference
Jennifer Vermette
1 reference
Richat Abbas
1 reference
Susan Quinn
1 reference
Christine Powell
1 reference
Howard A Burris
1 reference
24 March 2009
1 reference
15
1 reference
7
1 reference
2552-2558
1 reference